Combining Organoid Models with Next-Generation Sequencing to Reveal Tumor Heterogeneity and Predict Therapeutic Response in Breast Cancer

Figure 1

Diagnosis and treatment of metastatic ER+ breast cancer in a 41-year-old woman. (a) Diagnosis and treatment timeline. The blue arrow tips represent the gathering of tumor samples for the sequencing and cultivation of organoids. The red arrow tips denote the time points conducting organoids drug screen; (b) Tumor CT scan pictures.The red arrow denotes the tumor; (c) A gross chart displaying the surgical impact. Cells with irregular shapes are seen in CSF, indicating BC brain metastases. Scale bar, 10 μm.

(a)

(b)

(c)